Cargando…
ODP517 Successful Treatment of Myxedema Coma after SARS-CoV-2 infection with Combination Oral Levothyroxine and Liothyronine
INTRODUCTION: Myxedema coma (MC) is a rare, extreme form of hypothyroidism. It can be triggered by numerous factors including severe illness, trauma and infection. With the emergence of COVID, one may ask if COVID infection can lead to myxedema coma. Prompt infusion of levothyroxine is the consensus...
Autores principales: | Dimayuga, Diana Colleen, Villa, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629279/ http://dx.doi.org/10.1210/jendso/bvac150.1617 |
Ejemplares similares
-
SAT475 Levothyroxine and Liothyronine Treated Myxedema Coma with Irreversible Cardiopulmonary Failure: A Rare Phenomenon
por: Menon, Trisha, et al.
Publicado: (2023) -
SUN-550 Pressor Refractory, Liothyronine Responsive Myxedema Cardiogenic Shock without Myxedema Coma
por: Willis, Cornelia, et al.
Publicado: (2019) -
ODP491 Levothyroxine Withdrawal Presenting as Myxedema Madness
por: Trusty, Rhonda-Kaye, et al.
Publicado: (2022) -
SAT-460 Myxedema Coma Mimicking Cardiogenic Shock Treated with Levothyroxine
por: Chaker, Bayan, et al.
Publicado: (2020) -
ODP499 Myxedema Coma: A Challenging Presentation of an Uncommon Disease
por: Figueroa, Alegyari, et al.
Publicado: (2022)